Found 17 articles for: "UNCOVER-1"
Palmoplantar Pustulosis: Therapy Update
August 2024 | Volume 23 | Issue 8 | Original Article | 626 | Copyright © August 2024
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic ...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreIndividual Article: Brodalumab Is an Efficacious, Safe, and Cost-Effective IL-17 Receptor Blocker for the Treatment of Moderate-to-Severe Plaque Psoriasis: 2023 Update
October 2023 | Volume 22 | Issue 10 | Supplement Individual Articles | SF378632s5 | Copyright © October 2023
Psoriasis remains a highly prevalent condition in the United States and worldwide. Preclinical research has been triumphant in elucidating the critical immunological pathways involved in psoriasi...
Read MoreOnset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read MoreTreatment of Scalp Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 833 | Copyright © August 2022
Scalp involvement is seen in a majority of individuals with psoriasis, a chronic autoimmune skin disease with variable phenotypes. Occasionally, isolated scalp involvement is observed; and this causes...
Read MoreAdjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab
March 2022 | Volume 21 | Issue 3 | Original Article | 235 | Copyright © March 2022
Objective: To examine the effectiveness and safety of adjunctive treatment with calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam in adult patients with chronic pla...
Read MoreEarly Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
February 2022 | Volume 21 | Issue 2 | Original Article | 122 | Copyright © February 2022
Background: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.
O...
Read MoreBiological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
October 2021 | Volume 20 | Issue 10 | Original Article | 1063 | Copyright © October 2021
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We re...
Read MoreSustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
August 2021 | Volume 20 | Issue 8 | Original Article | 880 | Copyright © August 2021
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoria...
Read MoreEffect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies
April 2021 | Volume 20 | Issue 4 | Original Article | 394 | Copyright © April 2021
Objective: We describe patient-reported outcomes and quality of life through 5 years of treatment in patients with moderate-to-severe plaque Read More
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
August 2020 | Volume 19 | Issue 8 | Original Article | 741 | Copyright © August 2020
Background: Presence of nail psoriasis in patients with plaque psoriasis may be an indicator of greater disease severity. Previously, patients with nail psoriasis have had delayed ski...
Read MoreThe Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
August 2020 | Volume 19 | Issue 8 | Original Article | 703 | Copyright © August 2020
Background: Metabolic syndrome (MetS) is the most prevalent comorbidity in psoriasis and increases the risk of cardiovasc...
Read MoreReal-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab
February 2020 | Volume 19 | Issue 2 | Original Article | 132 | Copyright © February 2020
Psoriasis is a chronic, inflammatory, remitting/relapsing autoimmune dermatologic condition that manifests with scaly, erythematous plaques. It has a significantly negative effect on patient quality o...
Read MoreARTICLE: IL-23 Versus IL-17 in the Pathogenesis of Psoriasis: There Is More to the Story Than IL-17A
August 2019 | Volume 18 | Issue 8 | Supplement Individual Articles | 202 | Copyright © August 2019
Our understanding of psoriasis pathogenesis has evolved considerably. Cytokines within the TH1 and TH17 pathways have been found to be critical in psoriasis immunopathology. The TH17 pathway, which is...
Read MoreSafety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials
February 2018 | Volume 17 | Issue 2 | Original Article | 200 | Copyright © February 2018
BACKGROUND: Injection-site reactions (ISRs) are reported with biologic therapies. The objective of this study was to comprehensively characterize ISRs among moderate-to-severe psoriasis patients tr...
Read MoreCost-Effectiveness Analysis of Ixekizumab vs Etanercept and Their Manufacturer-Recommended Dosing Regimens in Moderate to Severe Plaque Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 964 | Copyright © October 2017
INTRODUCTION: Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Fo...
Read MoreTime to Raise the Bar to Psoriasis Area Severity Index 90 and 100
October 2015 | Volume 14 | Issue 10 | Editorials | 1086 | Copyright © October 2015
Media and other results for: "UNCOVER-1"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.